for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Histogenics Corp

HSGX.OQ

Latest Trade

0.23USD

Change

0.01(+2.27%)

Volume

157,934

Today's Range

0.22

 - 

0.23

52 Week Range

0.08

 - 

1.43

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.22
Open
0.23
Volume
157,934
3M AVG Volume
122.81
Today's High
0.23
Today's Low
0.22
52 Week High
1.43
52 Week Low
0.08
Shares Out (MIL)
94.60
Market Cap (MIL)
20.81
Forward P/E
--
Dividend (Yield %)
--

Next Event

Histogenics Corp Extraordinary Shareholders Meeting

Latest Developments

More

Entera Bio Appoints Adam Gridley As CEO

Histogenics Says Merger Agreement With Ocugen Amended To Restate “Exchange Ratio” To Be 28.7650

Histogenics Says Request To Continue Listing On Nasdaq Capital Market Granted By Nasdaq Panel

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Histogenics Corp

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient's own cartilage cells through a series of tissue engineering processes. The patient's cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company's Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Industry

Biotechnology & Drugs

Contact Info

830 Winter St

+1.781.4577900

http://www.histogenics.com/

Executive Leadership

Joshua J. Baltzell

Independent Chairman of the Board

Adam Gridley

President, Director

Donald Haut

Chief Executive Officer

Jonathan I. Lieber

Interim Chief Financial Officer

David C. Hood

Director

Key Stats

Price To Earnings (TTM)
1.14
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-90.94
Return on Equity (TTM)
-29.25

Latest News

BRIEF-Perceptive Advisors LLC Reports 8.8 pct Passive Stake In Histogenics As Of Jan. 17

* PERCEPTIVE ADVISORS LLC REPORTS 8.8 PERCENT PASSIVE STAKE IN HISTOGENICS CORP AS OF JANUARY 17, 2018 - SEC FILING Source text - (http://bit.ly/2GlVfLJ) Further company coverage:

BRIEF-Histogenics Announces Pricing Of Underwritten Registered Direct Offering

* ANNOUNCES PRICING OF UNDERWRITTEN REGISTERED DIRECT OFFERING OF 2,340,430 SHARES OF COMMON STOCK

BRIEF-Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan

* HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET

BRIEF-MEDINET signs license contract for NeoCart with Histogenics

* Says it entered into a license contract for development and sale of autologous cultured chondrocyte named NeoCart, with Histogenics Corp

BRIEF-Histogenics Corp announces Q3 loss per share $0.23

* Histogenics Corporation announces third quarter 2017 financial and operating results

BRIEF-Histogenics Corp promotes Stephen Kennedy to COO

* Histogenics Corporation promotes Stephen Kennedy to executive vice president & chief operating officer Source text for Eikon: Further company coverage:

BRIEF-Histogenics says Q2 loss per share $0.25

* Histogenics corporation announces second quarter 2017 financial and operating results

BRIEF-Histogenics on track for top-line one year superiority data, potential BLA filing in Q3 of 2018

* Histogenics completes enrollment for phase 3 clinical trial of neocart® to treat knee cartilage damage

BRIEF-Histogenics Corp appoints Donald Haut chief business officer

* Histogenics Corporation announces the appointment of Donald Haut, Ph.D. as chief business officer Source text for Eikon: Further company coverage:

BRIEF-Histogenics posts Q1 loss per share $0.27

* Histogenics Corporation announces first quarter 2017 financial and operating results

BRIEF-Histogenics files for mixed shelf of up to $50 mln

* Files for mixed shelf of up to $50 million - sec filing Source text for Eikon: Further company coverage:

BRIEF-Histogenics Corporation Q4 loss per share $0.63

* Histogenics Corporation announces financial and operating results for the fourth quarter and year ended December 31, 2016

BRIEF-Histogenics publishes data from human engineered cartilage testing

* Histogenics - data demonstrate co's tissue engineered cartilage constructs show mechanical properties approaching native human cartilage Source text for Eikon: Further company coverage:

BRIEF-Histogenics announces publication of MRI data from NeoCart phase 1, phase 2 clinical trials in American journal of sports medicine

* Histogenics announces publication of MRI data from Neocart phase 1 and phase 2 clinical trials in the American journal of sports medicine

BRIEF-Histogenics Corp posts Q3 loss per share of $0.70

* Believes its current cash position will fund its operations into middle of 2018

BRIEF-Histogenics provides Neocart phase 3 clinical trial enrollment update

* Histogenics - has enrolled 183, or approximately three-quarters, of 245 patients required to complete enrollment of its ongoing Neocart Phase 3 clinical trial Source text for Eikon: Further company coverage:

BRIEF-Histogenics says announces addition of Dr. Lawrence Bonassar to scientific advisory board

* Histogenics Corporation announces addition of Dr. Lawrence Bonassar of Cornell University to its scientific advisory board Source text for Eikon: Further company coverage:

BRIEF-Histogenics Corp files for 26.8 mln common stock offering

* Histogenics Corp files for 26.8 million common stock offering - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Histogenics Corporation announces $30 million private placement

* Histogenics Corporation announces $30.0 million private placement

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up